Compare MCO & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCO | TAK |
|---|---|---|
| Founded | 1900 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4B | 69.1B |
| IPO Year | 1998 | 2007 |
| Metric | MCO | TAK |
|---|---|---|
| Price | $470.14 | $21.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 3 |
| Target Price | ★ $553.67 | $24.48 |
| AVG Volume (30 Days) | 765.2K | ★ 3.1M |
| Earning Date | 10-21-2026 | 10-29-2026 |
| Dividend Yield | 0.87% | ★ 1.12% |
| EPS Growth | ★ 21.40 | N/A |
| EPS | ★ 12.98 | N/A |
| Revenue | ★ $4,204,100,000.00 | N/A |
| Revenue This Year | $6.50 | $4.79 |
| Revenue Next Year | $6.70 | $2.44 |
| P/E Ratio | ★ $36.35 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $402.28 | $14.16 |
| 52 Week High | $546.88 | $21.86 |
| Indicator | MCO | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 69.50 |
| Support Level | $460.33 | $17.66 |
| Resistance Level | $476.73 | N/A |
| Average True Range (ATR) | 12.25 | 0.33 |
| MACD | -5.50 | -0.01 |
| Stochastic Oscillator | 3.58 | 82.22 |
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and often (depending on bond issuance levels) a majority of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.